Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Friday. The company traded as high as $6.37 and last traded at $6.2250, with a volume of 197,077 shares traded. The stock had previously closed at $6.32.
Wall Street Analyst Weigh In
CTKB has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a research report on Monday, September 21st. Morgan Stanley set a $5.00 price target on Cytek Biosciences in a report on Friday, August 7th. Wall Street Zen upgraded Cytek Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Stephens upped their price objective on Cytek Biosciences from $6.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, November 10th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cytek Biosciences presently has a consensus rating of “Hold” and an average target price of $5.67.
Read Our Latest Research Report on Cytek Biosciences
Cytek Biosciences Trading Down 3.3%
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. Cytek Biosciences had a negative net margin of 39.10% and a negative return on equity of 13.13%. The company had revenue of $53.23 million for the quarter, compared to analysts’ expectations of $53.05 million. As a group, equities research analysts anticipate that Cytek Biosciences, Inc. will post -0.28 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cytek Biosciences
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Cytek Biosciences during the 2nd quarter worth $42,433,000. Hhlr Advisors LTD. bought a new stake in Cytek Biosciences during the second quarter worth about $29,491,000. Dimensional Fund Advisors LP lifted its position in Cytek Biosciences by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,663,329 shares of the company’s stock worth $11,638,000 after purchasing an additional 16,438 shares during the period. Russell Investments Group Ltd. lifted its position in Cytek Biosciences by 60.7% during the third quarter. Russell Investments Group Ltd. now owns 2,428,747 shares of the company’s stock worth $14,475,000 after purchasing an additional 917,432 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in Cytek Biosciences by 7.2% during the third quarter. Goldman Sachs Group Inc. now owns 2,323,524 shares of the company’s stock worth $13,848,000 after buying an additional 156,009 shares in the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.
About Cytek Biosciences
Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.
Further Reading
- Five stocks we like better than Cytek Biosciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
